FDA Accepts New Drug Application for Nubeqa Combo for Prostate Cancer Subset Darlene Dobkowski, MA The FDA will review an application to consider potential approval of Nubeqa plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer....
Although second-generation AR antagonists have become mainstays for the treatment of both CSPC and CRPC patients, their clinical benefits have been limited by potential side effects and especially by induced drug resistance. As mentioned above, the long half-lives and high levels of enzalutamide and...
Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results . Eur Urol (Suppl 2) 1993 ; 24 : 106 – 112 .Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol ...
Studies are already underway to address this critical challenge, including a crossover trial that has provided essential evidence that the sequence of abiraterone (plus prednisone) before enzalutamide was associated with longer time to second PSA progression than the reverse sequence40. Comprehensive ...
The article discusses a study which compared the efficacy and safety of cabazitaxel plus prednisone with those of motoxantrone plus prednisone in men suffe... D Bono,J Sebastian - 《Lancet》 被引量: 2411发表: 2010年 Prostate cancer radiation dose response: results of the M. D. Anderson pha...
The aim of this work was to characterise actuarial incidence and prevalence of early and late side effects of local versus pelvic three-dimensional conformal postoperative radiotherapy for prostate cancer. Based on arisk-adapted protocol, 575 patients received either local (n= 447) or local-plus-pe...
James (not real name) is a 58-year-old Indonesian. His problem started in early 2016 when he lost his appetite, felt fatigue and lost weight. Blood test showed his PSA was more than 500 and his alkaline phosphatase was 200 plus.
D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.JAMA. 2004;292(7):821-827. doi:10.1001/jama.292.7.821...
et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017). CAS PubMed Google Scholar James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 ...
Unfortunately, radical prostatectomy, the conventional surgical technique that aims to resect the cancerous tissues to improve the survival rate, can be too aggressive, cause serious side effects such as urinary incontinence and sexual dysfunction, and impair patients’ quality of life3. In contrast,...